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Abstract
Background: Osteoarthritis (OA) is a degenerative joint disease produced by a cascade of events that can ultimately
lead to joint damage. The aim of this study was to evaluate the effect of adelmidrol, a synthetic palmitoylethanolamide
analogue, combined with hyaluronic acid on pain severity and modulation of the inflammatory response in a rat
model of monosodium iodoacetate (MIA)-induced osteoarthritis.
Methods: OA was induced by intra-articular injection of MIA in the knee joint. On day 21 post-MIA administration, the
knee joint was analyzed. Rats subjected to OA were treated by intra-articular injection of adelmidrol in combination
with sodium hyaluronate at different doses and time points after MIA induction. Limb nociception was assessed by the
paw withdrawal latency and threshold measurement. Samples were examined macroscopically, histologically, and by
immunohistochemistry.
Results: At day 21 post-MIA injection, the MIA + solvent and MIA + 1.0% sodium hyaluronate groups showed
irregularities and fibrillation in the surface layer, a decrease in blood cells and multilayering in transition and radial
zones, no pannus formation, and modified Mankin scores significantly higher than sham knees. The combination
of hyaluronic acid and adelmidrol dose-dependently (adelmidrol 0.6% + 1.0% sodium hyaluronate and adelmidrol
2% + 1.0% sodium hyaluronate) reduced the histological alterations induced by MIA. Moreover, degeneration of
articular cartilage, mast cell infiltration, and pro-inflammatory cytokine and chemokine plasma levels were significantly
downregulated by treatment with a combination of hyaluronic acid and adelmidrol at the above doses.
Conclusions: Our results clearly demonstrate that the combination of hyaluronic acid and adelmidrol improves the
signs of OA induced by MIA.
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Background
Osteoarthritis (OA) is one of the most common joint
disabling disorders in adults [1]. It occurs when the pro-
tective cartilage on the ends of bones breaks down, caus-
ing pain, swelling, and problems in joint articulation [2].
OA is primarily characterized by degeneration of cartil-
age at the joints but also implicates other pathological
changes, including synovial inflammation, osteophyte
formation, and subchondral bone sclerosis, in all tissues
of joints [3–5]. OA can affect any joint, but the disorder
most frequently affects joints in the hands, knees, hips,
and spine, where it induces stiffness and joint dysfunc-
tion. Current guidelines defined by The Osteoarthritis
Research Society International state that OA treatment
should be aimed at reducing pain and joint stiffness,
maintaining and improving joint mobility, reducing
physical disability, and improving patient quality of life
by limiting progression of damage [6].
The monosodium iodoacetate (MIA) experimental
model is commonly used as an animal model of arthritis
pain associated with OA [7]. In particular, the MIA model
has been widely used for the pharmacological evaluation
of new drug therapy [8]. Nonsteroidal anti-inflammatory
drugs (NSAIDs) and steroids reduce the OA symptoms of
joint pain and swelling [9]. However, evidence in clinics
shows that pharmacological interventions, including acet-
aminophen, NSAIDS, topical agents, and intra-articular
injections (e.g., steroids), and non-pharmacological in-
terventions, such as joint replacement, are both sparse
and controversial [10–12]. Glucocorticoids (GCs) have
powerful immunosuppressive effects and are widely
used in the management of chronic inflammatory dis-
eases. Long-term therapy with GCs is often necessary
to control the symptoms of osteoarthritis [13]. Import-
ant evidence shows that GCs are also used in associ-
ation with hyaluronic acid (HA) and partially show an
ability to reduce pain as well as the progression of dis-
ease [14]. A number of studies suggest that HA associ-
ated with GCs might have a beneficial effect partially
related to a viscoelastic lubricant effect [15, 16].
A major drawback in the use of HA relates to the ability
of the intra-articular environment to depolymerize the
polysaccharide with a speed directly proportional to the
degree of intra-articular inflammation. The correct degrad-
ation of HA is therefore essential to maintain the integrity
of tissues and, in particular, joint homeostasis. Moreover,
an important question mark remains about therapeutic
management of long-term pathologies, with steroids often
linked to a series of unwanted side effects [17].
Adelmidrol is a semisynthetic derivative of azelaic
acid and analogue of the anti-inflammatory compound
palmitoylethanolamide (PEA), an aliamide and member
of the family of fatty acid amide signaling molecules
with cannabimimetic properties. The anti-inflammatory
and antinociceptive effects of the aliamides PEA and
adelmidrol have been demonstrated in numerous pre-
clinical studies, both in vitro and in vivo [18–20]. Their
actions are thought to be due, at least in part, to their
ability to down-modulate mast cell activation and mast
cell mediator release in pathophysiological and patho-
logical conditions [21].
The aim of the present study was to demonstrate that
adelmidrol in association with HA is able to control
depolymerization of exogenous HA, by bringing about a
viscoelastic-type lubricating action and consequent
modulation of inflammatory processes and pain in a rat
model of MIA-induced OA.
Methods
Animals
Forty male Lewis rats (Sprague-Dawley, 200–230 g;
Harlan, Nossan Milan, Italy) were maintained in a mon-
itored environment and provided with standard rodent
chow and water. The study was authorized by the Uni-
versity of Messina Review Board for the care of animals
(Protocol number 8/U-apr16). Animal care was in con-
formity with Italian regulations for the protection of
experimental animals (DM 116192) and with European
Economic Community regulations (OJ of EC L 358/1
12/18/1986).
Experimental protocol
OA was induced by intra-articular injection of MIA in
the knee joint [22]. On day 0, rats were anesthetized
with 5.0% isoflurane (Baxter International). A volume of
25 μl sterile saline solution + 3 mg MIA was injected
into the knee joint through the right infrapatellar liga-
ment. The left knee received an equal volume of 0.9%
sterile saline. MIA was prepared in sterile conditions
and injected using a 50-μl Hamilton syringe with a 27-
gauge needle that was inserted into the joint to about 2–
3 mm. On day 21 post-MIA administration, knee joints
were inspected in detail to determine histopathological
changes. Cartilage was stained to verify the presence of
OA or not.
Experimental groups
Rats were randomly divided into the following groups:
MIA + vehicle (solvent solution)
Rats were subjected to induction of OA as described
above, and received 25 μl of the solvent solution in the
infrapatellar area of the right knee at days 3, 7, 14, and
21 (n = 10) by intra-articular injection.
MIA adelmidrol 0.6% + 1.0% sodium hyaluronate
Rats were subjected to induction of OA as described
above, and were treated by intra-articular injection of
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adelmidrol 0.6% + sodium hyaluronate 1.0% (sodium
hyaluronate with high molecular weight, between 1.5
and 2.0 million daltons) at a dose of 150 μg/25 μl on
days 3, 7, 14, and 21 after MIA induction (n = 10)
MIA adelmidrol 2% + sodium hyaluronate 1.0%
Rats were subjected to induction of OA as described
above, and were treated by intra-articular injection of
adelmidrol 2% + sodium hyaluronate 1.0% (sodium hya-
luronate with high molecular weight, between 1.5 and
2.0 million daltons) at a dose of 150 μg/25 μl on days 3,
7, 14, and 21 after MIA induction (n = 10)
MIA + sodium hyaluronate 1.0%
Rats were subjected to induction of OA as described
above, and were treated by intra-articular injection of so-
dium hyaluronate 1.0% (sodium hyaluronate with high
molecular weight, between 1.5 and 2.0 million daltons)
at a dose of 150 μg/25 μl on days 3, 7, 14, and 21 after
MIA induction (n = 10)
Sham group
Rats were administered by intra-articular injection with
0.9% saline (25 μl) instead of MIA and were treated with
either vehicle or different formulations on days 3, 7, 14,
and 21 (n = 10)
Pain measurement
Mechanical sensitivity was evaluated using a dynamic
plantar aesthesiometer (Ugo Basile, Comerio, Italy). The
rats were placed on a metal mesh surface in a chamber
in a room with a controlled temperature (22 °C) and
they were allowed to adapt for 15 min before the testing
began. The touch stimulator part was oriented under the
animal. When the aesthesiometer was activated, a plastic
monofilament touched the paw in the proximal metatarsal
region. The filament exercised a gradually increasing force
on the plantar, starting below the threshold of detection
and increasing until the stimulus became painful and the
rat removed its paw. The force required to produce a paw
withdrawal reflex was recorded automatically and mea-
sured in grams. A maximum force of 50 g and a ramp
speed of 20 s were used for all the aesthesiometry tests.
Analysis of motor function (Walking Track Analysis)
The rat was placed in a walking track with a dark end.
White office paper of the appropriate size was placed on
the bottom of the track. Hind limbs of the rat were
dipped in ink, and the rat was allowed to walk along the
track, leaving paw prints on the paper. The test was per-
formed before induction on day 0 and at days 3, 7, 14,
and 21 after induction [23]. The functionality index of
the sciatic nerve (SFI), calculated by Walking Track
Analysis, was evaluated at 60 min after the injection on
days 3, 7, 14, and 21: values close to 0 indicate normal
functioning, and values tending to –100 indicate an al-
teration of sciatic nerve functionality [24].
Micro-computed tomography analysis
In order to evaluate the bone mass and microarchitec-
ture parameters, including the fraction of bone volume,
the proximal and distal parts of the right tibiae were
scanned using micro-computed tomography (Micro-CT;
Skyscan, Belgium) The scan conditions were as follows:
an aluminum filter of 0.5 mm, X-ray voltage of 50Kv, X-
ray current of 200 mA, and an exposure time of 360 ms.
After scanning, the cross-sectional slices were recon-
structed and three-dimensional analyses were performed
using CTAn SkyScan software.
Histological analysis
On day 21 after MIA administration, rats were sacrificed
by anesthetic overdose and perfused with 4% parafor-
maldehyde solution. Tibiofemoral joints were collected
and post-fixed in neutral buffered formalin (containing
4% formaldehyde), decalcified in EDTA, and processed
as following described. After decalcification, the speci-
mens were embedded in paraffin. Mid-coronal tissue
sections (5 μm) were stained for evaluation; all histo-
morphometric analyses were performed by an observer
blinded to the treatment groups. Sections were stained
with hematoxylin and eosin and observed by light micros-
copy (Dialux 22 Leitz; Leica Microsystems SpA, Milan,
Italy). Histopathological analysis of the cartilage was
assessed by the modified score of Mankin [14] (score
range 0 to 12, from normal to complete disorganization
and hypocellularity).
Cartilage degeneration was assessed by staining with
toluidine blue and analyzed using the following criteria
described by Janusz et al. [25]: 1 = mild into the surface
region; 2 = slightly extended in the upper center; 3 =mod-
erate in the median area; 4 = extended area deep; and
5 = severe degeneration.
Mast cell staining
Identification of mast cells was performed as described
previously [26]. Knee sections were cut at 5-μm thick-
ness and stained with 0.25% toluidine blue, pH 2.5, for
45 min at room temperature. The sections were then
dehydrated and mounted for viewing. Three non-
sequential sections were chosen by a block at random
from each paw for examination. All sections were evalu-
ated at 200×, while some sections were photographed at
400× using a Nikon inverted microscope. The density of
mast cells is expressed as the number of mast cells per
unit area of bone tissue.
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Measurement of cytokines, metalloproteinases, and nerve
growth factor
The levels of tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, nerve growth factor (NGF), and matrix metallo-
proteinase (MMP)-1, MMP-3, and MMP-9 were measured
in serum. Assays were performed using commercial colori-
metric enzyme-linked immunosorbent assay (ELISA) kits
(TNF-α, IL-1β, and NGF: Thermo Fisher Scientic; MMP-1,
MMP-3, and MMP-9: Cusabio).
Reagents
Unless otherwise stated, all compounds were obtained
from Sigma-Aldrich Co. All other chemicals were of the
highest commercial grade available. All stock solutions
were prepared in non-pyrogenic saline (0.9% NaCl; Bax-
ter Healthcare Ltd., Thetford, Norfolk, UK).
Data analysis
All values in the figures and text are expressed as mean
± standard error of the mean (SEM) of n observations.
For in vivo studies, n represents the number of animals
studied. In experiments involving histology, the figures
shown are representative of at least three experiments
performed on different days. The results were analyzed
by one-way analysis of variance (ANOVA) followed by a
Bonferroni post-hoc test for multiple comparisons. Non-
parametric data were analyzed with the Fisher's exact
test. A P value less than 0.05 is considered significant.
Results
Effects of the HA and adelmidrol combination on OA pain
production and motor function
Because pain is the predominant symptom of OA, the
secondary tactile allodynia in MIA-induced OA rats was
assessed. In the von Frey hair assessment test, the paw
withdrawal latency (PWL) (Fig. 1b) and the paw with-
drawal threshold (PWT) (Fig. 1a) were significantly pro-
longed in the inflamed hind paw of the rats given 0.6%
adelmidrol + 1.0% sodium hyaluronate and 2% adelmi-
drol + 1.0% sodium hyaluronate compared with the MIA
Fig. 1 Effects of sodium hyaluronate (Na hyaluronate) and adelmidrol
(Adel.) combination on OA pain production and motor function. In the
von Frey hair assessment test, the paw withdrawal threshold (PWT) (a)
and the paw withdrawal latency (PWL) (b) were prolonged significantly
in the inflamed hind paw of the rats given 0.6% adelmidrol + 1.0%
sodium hyaluronate and 2% adelmidrol + 1.0% sodium hyaluronate
compared with the monosodium iodoacetate (MIA) + solvent group
and MIA + sodium hyaluronate 1.0% group. The sham group showed
no obvious change. c In the MIA + vehicle and 1.0% sodium hyaluronate
groups, the sciatic nerve functionality index (SFI) values were significantly
lower than in sham animals. Treatment with a combination of HA acid
and adelmidrol improved motor function in a dose-dependent manner.
Data are means ± S.E.M. of 10 rats for each group. *P< 0.05 versus sham,
°P< 0.05 versus MIA + vehicle
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+ solvent group and the MIA + sodium hyaluronate 1.0%
group, demonstrating the antinociceptive property of
adelmidrol in a dose-dependent manner. The sham
group showed no obvious change (Fig. 1a and b).
Moreover, we tested motor function using a walking
track in order to demonstrate that the association of
adelmidrol with sodium hyaluronate treatment may im-
prove joint mobility and reduce physical disability. Ana-
lysis was performed on days 3, 7, 14, and 21 after
induction of OA. As shown in Fig. 1c, the SFI in the
sham group was normal throughout the experiment,
with SFI approximating 0. In the MIA + vehicle and 1.0%
sodium hyaluronate groups, SFI values on post-MIA ad-
ministration on days 3, 7, 14, and 21 were significantly
lower than those observed in the sham group. The com-
bination of HA and adelmidrol (0.6% adelmidrol + 1.0%
sodium hyaluronate and 2% adelmidrol + 1.0% sodium
hyaluronate) dose-dependently improved motor function
(Fig. 1c).
Effects of the HA and adelmidrol combination on plasma
levels of pro-inflammatory cytokines and NGF
To test whether the association of adelmidrol with so-
dium hyaluronate treatment may modulate the secretion
of pro-inflammatory cytokines, we analyzed plasma
levels of TNF-α, IL-1β, and NGF. A significant increase
in serum levels of TNF-α (Fig. 2a), IL-1β (Fig. 2b), and
NGF (Fig. 2c) was observed in the MIA + vehicle and 1%
sodium hyaluronate groups compared to sham animals.
In contrast, the HA and adelmidrol combination (0.6%
adelmidrol + 1.0% sodium hyaluronate and 2% adelmi-
drol + 1.0% sodium hyaluronate) dose-dependently re-
duced the increase in serum levels of TNF-α (Fig. 2a),
IL-1β (Fig. 2b), and NGF (Fig. 2c) after administration of
MIA.
Effects of the HA and adelmidrol combination on mast
cell infiltration
An important source of cytokines, specifically TNF-α
and IL-1β, is characterized by mast cell activation. Mast
cell infiltration after OA induction was studied by stain-
ing knee joint tissues with toluidine blue. Degranulated
mast cells were not seen in knee sections from the sham
Fig. 2 Effects of the combination of hyaluronic acid and adelmidrol
on plasma cytokines and nerve growth factor (NGF) in osteoarthritis
(OA) rats. MIA-induced OA and tissue sample processing were carried
out as detailed in the Methods section. Increased tumor necrosis factor
alpha (TNF-α) (a), interleukin-1beta (IL-1β) (b), and NGF (c) plasma
levels were detected in the MIA + solvent and MIA + 1.0% sodium
hyaluronate groups after MIA administration. OA rats treated with
the indicated doses of adelmidrol and HA exhibited a dose-dependent
reduction in the plasma levels of all the measured parameters. Values
are shown as mean ± SEM of 10 animals for each group. *P < 0.05
versus sham, °P < 0.05 versus MIA + vehicle.
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group (Fig. 3a; mast cell density in Fig. 3f ). On the con-
trary, significant mast cell infiltration was observed in
the MIA + solvent (Fig. 3b) and MIA + 1.0% sodium
hyaluronate (Fig. 3c) groups in joint tissue near the
subchondral bone taken 21 days after the induction of
OA. The combination of HA and adelmidrol (0.6%
adelmidrol + 1.0% sodium hyaluronate and 2% adelmi-
drol + 1.0% sodium hyaluronate) (Fig. 3d and e) dose-
dependently reduced mast cell infiltration induced by
administration of MIA.
Effects of the HA and adelmidrol combination on plasma
levels of metalloproteinases
The progressive destruction of articular cartilage is
caused by a number of matrix-degrading enzymes pro-
duced by the chondrocytes and synovium. Among the
various biomarkers associated with OA, MMPs play a
primary role in the downstream signaling pathways in
OA and cartilage degradation. The MIA + vehicle and
1% sodium hyaluronate group showed a markedly higher
expression of MMP-1 (Fig. 4a), MMP-3 (Fig. 4b), and
MMP-9 (Fig. 4c). However, compared to the MIA
group, the group treated with 0.6% adelmidrol + 1.0%
sodium hyaluronate and, in particular, 2% adelmidrol
+ 1.0% sodium hyaluronate showed a decrease in
MMP-1, MMP-3, and MMP-9 expression (Fig. 4a, b
and c, respectively).
Effects of the HA and adelmidrol combination on OA
articular cartilage degeneration
As indicated by toluidine blue O staining (Fig. 5), MIA
intra-articular injection induced articular cartilage de-
generation on the medial tibia platform in the MIA +
solvent (Fig. 5b; cartilage degeneration scores in Fig. 5f )
and MIA + 1.0% sodium hyaluronate (Fig. 5c) groups.
Compared with knee joints in the MIA + solvent group,
knees in the 0.6% adelmidrol + 1.0% sodium hyaluronate
(Fig. 5d) group exhibited moderate cartilage degener-
ation; matrix and chondrocyte loss affected the middle
to deep zone. The group with the higher treatment dose
of 2% adelmidrol + 1.0% sodium hyaluronate showed no
statistical improvement in cartilage degeneration
(Fig. 5e). Sham knee joints (Fig. 5a) showed no obvious
changes.
Effects of the HA and adelmidrol combination on OA
subchondral bone
In order to demonstrate the crucial role of subchondral
bone in the pathogenesis and progression of OA, knee
sections 21 days after MIA induction were examined for
the number of osteoclasts and bone volume. In the MIA
+ solvent (Fig. 6b; cell number per joint in Fig. 6f ) and
MIA + 1.0% sodium hyaluronate (Fig. 6c) groups, the
number of osteoclasts was increased after MIA injection.
Compared with knee joints in the MIA + solvent group,
knees in the 0.6% adelmidrol + 1.0% sodium hyaluronate
(Fig. 6d) group exhibited a moderately increased number
of osteoclasts. The higher treatment dose of 2% adelmi-
drol + 1.0% sodium hyaluronate showed no statistical im-
provement in cell numbers (Fig. 6e). There is no
variation in cell numbers in Sham knee joints (Fig. 6a).
Moreover, to quantity the structural changes in the
subchondral bone in MIA-induced OA, each rat was
scanned for bone volume density (mm3) (Fig. 6g). Com-
pared with the MIA + solvent and MIA + 1.0% sodium
hyaluronate groups, 0.6% adelmidrol + 1.0% sodium
hyaluronate and the higher treatment dose of 2% adel-
midrol + 1.0% sodium hyaluronate showed a marked in-
crease in bone volume (Fig. 6g). Thus, treatment with
0.6% adelmidrol + 1.0% sodium hyaluronate and the
higher treatment dose of 2% adelmidrol + 1.0% sodium
hyaluronate showed significant and dose-dependent ef-
fects on MIA-induced deterioration of the subchondral
bone.
Fig. 3 Effects of the combination of hyaluronic acid and adelmidrol
on mast cell staining in osteoarthritis (OA) knee tissue. Compared
with sham knees (a), the MIA + solvent (b) and MIA + 1.0% sodium
hyaluronate (c) groups displayed significant increases in the numerical
density of toluidine blue-positive cells. In contrast, the combination of
HA and adelmidrol at the doses indicated (0.6% adelmidrol + 1.0%
sodium hyaluronate (d), and 2% adelmidrol + 1.0% sodium hyaluronate
(e)) produced a dose-dependent reduction in mast cell infiltration in
the knees of MIA-treated rats. (f) Number of mast cells per unit area of
muscle parenchyma (mast cell density). Data are means ± SEM of 10
rats for each group. *P < 0.05 versus sham, °P < 0.05
versus MIA + vehicle
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Effects of the HA and adelmidrol combination on OA
histopathology
In order to demonstrate that adelmidrol promotes the
beneficial and lubricant action of HA, knee sections
were stained with hematoxylin and eosin 21 days after
intra-articular injection of MIA. Histological examin-
ation by light microscopy showed irregularities and fib-
rillation in the surface layer, a decrease in blood cells
and multilayering in transition and radial zones, no pan-
nus formation, and modified Mankin scores (Fig. 7f ) in
the MIA + solvent and MIA + sodium hyaluronate 1.0%
knees groups (Fig. 7b and c, respectively; see Mankin
scores in Fig. 7f) compared to sham knees. The combin-
ation of HA and adelmidrol (0.6% adelmidrol + 1.0%
solium hyaluronate (Fig. 7d) and 2% adelmidrol + 1.0% so-
dium hyaluronate (Fig. 7e)) reduced, in a dose-dependent
manner, the histological alterations induced by adminis-
tration of MIA.
Discussion
OA is a complex disease with inflammatory mediators re-
leased by cartilage, bone, and synovium [27]. Numerous
inflammatory mediators contribute to both degradative
and nociceptive pathways associated with the progression
of pathology. Inflammatory stimuli initiate a cascade of
events, including the release of cytokines by chondrocytes,
leading to complex biochemical and mechanical interplay
with other biological mediators to induce OA and pro-
mote pain [27, 28].
Although the role of cytokines in the pathogenesis of
OA is not yet clear, several in vitro studies support an el-
evated catabolic role for cytokines in the OA joint. IL-1β
and TNF-α signaling, culminating in the activation of
nuclear factor-κB and activator protein 1 transcription
factors, can induce autocrine production of IL-1β and
TNF-α as well as expression of other critical inflamma-
tory and chrondrolytic mediators, including MMP1,
MMP9, MMP13, nitric oxide, prostaglandin E2, IL-6,
and pain [29].
Moreover it has been demonstrated that IL-1β induces
an increase in levels of NGF [30]. NGF is a key factor in
hyperalgesia associated with inflammation, whose pro-
tein is detected in OA synovial fluid [31]. NGF synthesis
Fig. 4 Effects of HA and adelmidrol combination on plasma levels of
matrix metalloproteinases (MMPs). MMPs play a primary role in the
downstream signaling pathways in osteoarthritis (OA) and cartilage
degradation. The MIA + vehicle and 1% sodium hyaluronate group
showed a markedly higher expression of MMP-1 (a), MMP-3 (b), and
MMP-9 (c). Compared to the MIA group, the group treated with
0.6% adelmidrol + 1.0% sodium hyaluronate and, in particular, with
2% adelmidrol + 1.0% sodium hyaluronate showed a decrease in
MMP-1, MMP-3, and MMP-9 expression (a–c, respectively). Data are
means ± SEM of 10 rats for each group. *P < 0.05 versus sham,
°P < 0.05 versus MIA + vehicle
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is highly correlated with the degree of cartilage degrad-
ation in human OA [32]. Clinical trials have demon-
strated that acting against NGF leads to a dramatic
reduction in OA pain [33]. In this study, we confirmed
an increase in cytokine production and showed that
treatment with HA in combination with adelmidrol in
increasing doses significantly reduced pro-inflammatory
cytokine levels and NGF expression.
The literature indicates that an important source of cy-
tokines, specifically TNF-α and IL-1β, is also characterized
by mast cell activation. There is a well-established correl-
ation between mast cell numbers and total inflammatory
infiltrate. Mast cells are potent regulators of vascular per-
meability and have a crucial role in the recruitment of leu-
kocytes to OA joints. Degranulated mast cells have been
found in OA synovium [34], and Buckley and Walls [35]
reported a selective expansion and higher ratio of mast
cell tryptase phenotype in OA synovium, a phenotype
consistent with degranulation.
The present study confirms an increased infiltration of
mast cells in the knee joint after MIA administration,
and their consequent reduction after treatment with HA
in combination with adelmidrol in increasing doses.
Mast cells in the joint capsule become hyper-reactive
due to joint inflammation, a process markedly influenced
by the degradation of HA caused by the in situ release
of β-hexosaminidase [36, 37]. In fact, OA animals and
those treated only with HA displayed a significant de-
generation of articular cartilage. Significant restoration
of cartilage was achieved after treatment with increasing
doses of HA and adelmidrol in combination.
Along with progressive loss of articular cartilage, OA is
characterized by increased subchondral bone sclerosis with
thickening of the cortical plate, extensive remodeling of the
trabeculae, formation of new bone at the joint margins
(osteophytes), and the development of subchondral bone
cysts. Changes to subchondral bone are due to increased
osteoclastic bone resorption and changes in bone density.
Fig. 5 Effects of the combination of hyaluronic acid and adelmidrol on cartilage degeneration in osteoarthritis (OA) knee tissue. MIA-induced OA
and tissue sample processing were carried out as detailed in the Methods section. No cartilage degeneration was observed in the sham group
(a). Significant histopathological changes were evident in the MIA + solvent (b) and MIA + 1.0% sodium hyaluronate (c) groups, as indicated by
surface irregularity, disorganization of articular cartilage with apparent cloning of chondrocytes in the transitional and radial zones, and an intact
tidemark. The combination of HA and adelmidrol at the doses indicated (0.6% adelmidrol + 1.0% sodium hyaluronate (d), and 2% adelmidrol + 1.0%
sodium hyaluronate (e)) significantly prevented damage to the cartilage structure, reduced cellular abnormalities, and prevented change of the
tidemark induced by administration of MIA. Cartilage degeneration scoring was performed by an independent observer (f). Data are means ± SEM of
10 rats for each group. *P < 0.05 versus sham, °P < 0.05 versus MIA + vehicle
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Our study demonstrated that adelmidrol and hyaluronic
acid treatment showed significant and dose-dependent ef-
fects on MIA-induced deterioration of the subchondral
bone, reducing osteoclastic bone resorption.
Strong evidence associates subchondral bone alterations
with cartilage damage and pain severity in OA [38]. In this
study, motor functionality was evaluated by Walking Track
Analysis. An SFI value of approximately zero indicates nor-
mal locomotor function, while a value close to –100 indi-
cates significant impairment of locomotor function. As
expected, intra-articular injection of MIA resulted in a sig-
nificant increase in joint discomfort. Importantly, the com-
bination of HA and adelmidrol, in a dose-dependent
fashion, completely restored locomotor functionality.
Fig. 6 Effects of hyaluronic acid and adelmidrol combination on the pathogenesis of subchondral bone. In the monosodium iodoacetate
(MIA) + solvent (b) and MIA + 1.0% sodium (Na) hyaluronate (c) knee groups, the number of osteoclasts was increased after MIA injection.
Compared with knee joints in the MIA + solvent group, knees in the 0.6% adelmidrol (Adelm) + 1.0% sodium hyaluronate (d) group exhibited moderately
increased numbers of osteoclasts. The higher treatment dose of 2% adelmidrol + 1.0% sodium hyaluronate showed no statistical improvement in cell
numbers (e). There is no variation in cell numbers in sham knee joints (a). f Cell number per joint. g Moreover to quantify the structural changes in the
subchondral bone in MIA-induced OA, each rat was scanned for bone volume density (mm3 ). Compared with the MIA + solvent and MIA + 1.0% sodium
hyaluronate groups, 0.6% adelmidrol + 1.0% sodium hyaluronate and higher treatment dose of 2% adelmidrol + 1.0% sodium hyaluronate showed a
marked increase in bone volume. Thus, treatment with 0.6% adelmidrol + 1.0% sodium hyaluronate and a higher treatment dose of 2% adelmidrol + 1.0%
sodium hyaluronate showed significant and dose-dependent effects on MIA-induced deterioration of the subchondral bone. Data are means ± SEM of 10
rats for each group. *P< 0.05 versus sham, °P< 0.05 versus MIA + vehicle
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Conclusions
Our results clearly demonstrated that a combination of
HA and adelmidrol dose-dependently produced a signifi-
cant reduction in: 1) pain severity; 2) OA histopathology;
3) articular cartilage degeneration; 4) mast cell infiltration;
5) pro-inflammatory cytokines, MMPs, and NGF produc-
tion; and 6) the degree of motor function.
The association of HA with adelmidrol is accom-
panied by a reduced depolymerization of HA, which
would otherwise be promoted by intra-articular
inflammation.
Moreover application of infiltrative adelmidrol produces
a significant increase in endogenous PEA levels [39],
which are found to be significantly reduced in joint in-
flammation [40]. Several of our works demonstrated the
beneficial effects of PEA alone and in combination in dif-
ferent models of inflammation and pain [41, 42], such as
in a mouse model of collagen-induced arthritis (CIA) [19].
Thus, local analgesic and anti-inflammatory effects
observed with adelmidrol treatment could be useful in the
treatment of inflammatory diseases associated with pain.
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